“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
A trial looking at trastuzumab (Herceptin) with chemotherapy for early breast cancer (SOLD)
This trial compared trastuzumab (Herceptin) and chemotherapy, to Herceptin and chemotherapy followed by more Herceptin. It was for women with early breast cancer that was HER2 positive. This trial was supported by Cancer Research UK.
More about this trial
- docetaxel chemotherapy and Herceptin at the same time to start with, then
- a combination of chemotherapy called FEC (fluorouracil, epirubicin and cyclophosphamide)
Summary of results
- half didn’t have any more Herceptin
- half had Herceptin for about another 10 months (so about a year in total)
- 88% of those who’d had Herceptin for 9 weeks
- 91% of those who’d had Herceptin for a year
- 73 women (7%) who’d had Herceptin for 9 weeks
- 61 women (6%) who’d had Herceptin for a year
- 34 women (3%) who’d had Herceptin for 9 weeks
- 33 women (3%) who’d had Herceptin for a year
- 22 women (2%) who had Herceptin for 9 weeks
- 42 women (4%) who had Herceptin for a year
- 63% for women who had Herceptin for 9 weeks
- 61% for women who had Herceptin for a year
How to join a clinical trial
Dr Judy fraser
This is Cancer Research UK trial number CRUKE/10/033.